Prodrugs-Current and Future Drug Development Strategy

Abstract

The focus of traditional prodrug approach was on altering various physiochemical parameters, whereas the current modern computational approach considers designing prodrugs through attaching appropriate linkers with drugs having poor bioavailability which upon exposure to physiological environments release the parent active drugs in a programmable (controlled) manner resulting in an improvement of their bioavailability. With the possibility of designing prodrugs with different linkers, the release rate of the parent active drugs can be controlled. The future of prodrug technology is exciting and yet challenging. Advances must be made in understanding the chemistry of many organic reactions that can be effectively utilized to enable the development of more types of prodrugs. The understanding of organic reaction mechanisms of certain processes, particularly intramolecular reactions, will be the next major milestone in this field. It is envisioned that the future of prodrug technology holds the ability to create safe and efficacious delivery of a wide range of active small molecules and biotherapeutics. This goal can be achieved using computational chemistry methods such as ab initio, semi-empirical and density functional theory (DFT), and molecular mechanics (MM) to calculate physicochemical and molecular properties of current marketed drugs suffer low bioavailability or/and unpleasant taste or odor.

Authors and Affiliations

Rafik Karaman

Keywords

Related Articles

Hypoparathyroidism, Brain Calcifications and Seizures

Background: The most common cause of hypoparathyroidism is iatrogenic in the context of surgical procedures to the neck and commonly the thyroid gland. Hypoparathyroidism is characterized by hypocalcaemia, hyperphosphate...

Osteitis Fibrosa Cystica of Jaws as Diagnostic Criteria for Hyperparathyroidism – A Case Report with Review of Literature

Maxillo-mandibular swellings are one the common presentations with which, patient approach a surgeon. These maxillo-mandibular swellings may be reactionary, benign, malignant and sometimes secondary to some underlying sy...

Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be the Last Word: Two Cases Illustrated

Over the past 20 years, the treatment for multiple myeloma (MM) has evolved significantly. These pharmaceutical developments allow physicians to combine existing chemotherapy with newly approved novel and targeted medica...

Decreasing the Types and Quantities of Oral Antiepileptic Drugs Administered Alongside Intravenous Midazolam

It is reported that 0.4 to 0.8% of the world’s population suffers from epilepsy. About 30% of epileptic patients are intractable. Controlling their seizures is very important for society because many patients can partici...

Implementing the Use of Ultrasonography Screening Markers of the Trisomy 18 in the Clinical Practice, in the Era of Non-invasive Prenatal Test: Case Reports

Introduction: Edwards’s syndrome (Tr18) is a genetic disorder caused by trisomy of the chromosome 18, and its penetrance is cc. 1:5000. This Edwards-syndrome or trisomy18 associated with many different conditions and abn...

Download PDF file
  • EP ID EP343872
  • DOI 10.9734/IJMPCR/2014/13183
  • Views 78
  • Downloads 0

How To Cite

Rafik Karaman (2014). Prodrugs-Current and Future Drug Development Strategy. International Journal of Medical and Pharmaceutical Case Reports, 1(2), 58-63. https://europub.co.uk/articles/-A-343872